Aalto Bio Reagents signed its first distribution agreement with a Chinese partner, Seebio Biotech Co Ltd, while on a Team Ireland led trade mission. This major trade mission, attended by An Tánaiste Simon Coveney, aims to build strategic relationships with potential business partners like Seebio Biotech. Irish trade with China has doubled in the last 4 years and with the Chinese in-vitro diagnostic market expected to triple by 2022, this presents an excellent opportunity for companies such as Aalto Bio Reagents to further expand its customer reach and to capitalise on this growth.
Aalto Bio already has a strong presence in the IVD market in Europe, and has recently expanded into Brazil, Japan, Korea and the U.S. with the growing demand for its tropical virus antigens and antibodies. Philip Noone, CEO of Aalto Bio Reagents, said “the signing of this first ever distribution agreement with a Chinese partner opens up a whole new territory for us and will help broaden our global presence.
Visit for More Reports on Diagnostics: http://www.dpiresearch.com/